These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1682040

  • 21. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 22. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S.
    J Natl Cancer Inst; 1992 Dec 16; 84(24):1915-22. PubMed ID: 1460673
    [Abstract] [Full Text] [Related]

  • 23. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L.
    Anticancer Drugs; 2012 Oct 16; 23(9):906-13. PubMed ID: 22926257
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
    Pinski J, Halmos G, Schally AV.
    Cancer Lett; 1993 Jul 30; 71(1-3):189-96. PubMed ID: 8103419
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
    Miyazaki M, Lamharzi N, Schally AV, Halmos G, Szepeshazi K, Groot K, Cai RZ.
    Eur J Cancer; 1998 Apr 30; 34(5):710-7. PubMed ID: 9713279
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV.
    Eur J Cancer; 1997 Jun 30; 33(7):1141-8. PubMed ID: 9376196
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Oncol; 2007 Apr 30; 30(4):1019-28. PubMed ID: 17332943
    [Abstract] [Full Text] [Related]

  • 31. [Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin].
    Zhang GF, Wang YH, Zhang MA, Wang Q, Luo YB, Wang DS, Han CR.
    Ai Zheng; 2002 Jan 30; 21(1):50-3. PubMed ID: 12500397
    [Abstract] [Full Text] [Related]

  • 32. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F.
    Cell Cycle; 2012 Jul 01; 11(13):2518-25. PubMed ID: 22751419
    [Abstract] [Full Text] [Related]

  • 33. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 34. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G.
    Anticancer Drugs; 2008 Apr 15; 19(4):349-58. PubMed ID: 18454045
    [Abstract] [Full Text] [Related]

  • 35. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
    Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 1999 Nov 15; 81(6):966-71. PubMed ID: 10576652
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.
    Cancer; 2000 Mar 15; 88(6):1384-92. PubMed ID: 10717621
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.
    Cancer Res; 1999 Apr 15; 59(8):1947-53. PubMed ID: 10213505
    [Abstract] [Full Text] [Related]

  • 39. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K, Schally AV, Groot K, Halmos G.
    Int J Cancer; 1993 May 08; 54(2):282-9. PubMed ID: 8387464
    [Abstract] [Full Text] [Related]

  • 40. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A, Schally AV.
    Cancer Res; 1989 Apr 01; 49(7):1810-5. PubMed ID: 2564312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.